Roquette Ventures and Advanced Protein Technologies have signed an agreement to work together on the development of new promising human breast milk components.
HMOs- Used to Manufacture Cosmetics
Human Milk Oligosaccharides (HMOs) are only found in human breast milk, constituting up to eight percent of the human milk with over 200 different types of structures. HMOs will not only be a major part of infant and child nutrition but also to be introduced into industries such as, cosmetics, pharmaceuticals, general food, and pet food.
“
This investment represents an important collaboration for us. As long-term strategic partner, we are driven by a strong desire to support pioneering innovations and to contribute to accelerating their development,” stated Edouard Nuttin, General Manager of Roquette Ventures.
AP Technologies to Start HMO Production
AP Technologies received its first investment from domestic venture capitals (KB Investment, Stone Bridge Capital, Intervalue Partners and Maple Venture Investment) in 2018 and built its HMO Campus in Hwaseong, Gyeonggi Province. This will be the Campus that carries out full-scale commercial HMO production and global sales starting next year.
“
This investment from Roquette Ventures confirms the strong interest of our differentiated technology to offer promising new ingredients of human breast milk,” commented Chul Soo, Shin, CEO of AP Technologies.
With this agreement, AP Technologies will embark on its long-term plans of entering the cosmetic, nutraceuticals, pet food and pharmaceutical market with products that generate immune activation, brain development and synergistic effects of the gut microbiome.
“
AP Technologies has a great growth potential and we are very pleased to be part of this journey to better answer Food, Health and Nutrition markets expectations worldwide. AP Technologies’ HMOs will definitely bring unique advantages and benefits to consumers,” added Nuttin.
Roquette's Product Portfolio
Source: Roquette Ventures